Amerise Biosciences Ltd

Amerise Biosciences Limited (formerly Amradeep Industries Limited) has announced its 41st Annual General Meeting (AGM) to be held on Thursday, September 24, 2026, at 3:00 PM in Ahmedabad. The meeting agenda includes the adoption of audited financial statements for the year ended March 31, 2026, and the reports of the Board of Directors and Auditors. A key item of special business is the proposed appointment of Mr. Albert Hines as Whole Time Director and Chief Financial Officer (CFO) effective February 2, 2026, for a period of three years, with nil remuneration. The company also provided details regarding proxy appointments, authorized representatives, and closure of the Register of Members.

Amerise Biosciences Ltd has announced its 41st Annual General Meeting (AGM) to be held on Thursday, September 24, 2026. The meeting will take place at the company's registered office in Ahmedabad. Key agenda items include the adoption of the audited financial statements for the fiscal year 2025-26, along with the reports of the Board of Directors and Auditors. Additionally, the members will vote on the appointment of Mr. Albert Hines as Whole-Time Director and Chief Financial Officer (CFO) for a period of three years, commencing February 2, 2026, with nil remuneration. The filing also includes the Notice of the AGM and the Annual Report for the financial year 2025-26.

Snehjeev Ventures Pvt Ltd, along with Persons Acting in Concert (PACs), has disclosed the acquisition of 7,292,684 equity shares in Amerise Biosciences Ltd. This acquisition represents a holding of 11.04% of the total capital of the target company as of August 14, 2026. The shares were acquired through the open market. Prior to this acquisition, the acquirer and PACs held 10.92% of the company's shares. The disclosure is made under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011.

Amerise Biosciences Ltd announced that its Board of Directors has approved the un-audited standalone financial results for the quarter ended June 30, 2026. The board meeting took place on August 3, 2026. The financial results were reviewed by the Audit Committee and approved by the Board. The Statutory Auditors have carried out a limited review. The company operates in a single segment.

Amerise Biosciences Ltd announced that its Board of Directors, in a meeting held on August 3, 2026, considered and approved the un-audited standalone financial results for the quarter ended June 30, 2026. The meeting commenced at 04:50 PM and concluded at 05:10 PM. The financial results have been reviewed by the Audit Committee and approved by the Board. The Statutory Auditors have also carried out a limited review. The company operates in a single segment.

Amerise Biosciences Ltd announced that its Board of Directors, in a meeting held on August 3, 2026, approved the un-audited financial results for the quarter ended June 30, 2026. The results were reviewed by the Audit Committee and have undergone a limited review by the statutory auditors. The company operates in a single segment. The board meeting commenced at 04:50 PM and concluded at 05:10 PM.

Snehjeev Ventures Pvt Ltd, along with its Persons Acting in Concert (PACs), has acquired an additional 0.04% stake in Amerise Biosciences Ltd through open market transactions. This acquisition brings their total shareholding to 9.02%. The transaction involved the purchase of 28,000 equity shares, increasing the acquirer's voting rights to 5,962,355 shares. The total equity share capital of Amerise Biosciences remains at Rs. 6,60,69,000/-.

Snehjeev Ventures Pvt Ltd, along with its persons acting in concert (PACs), has acquired 5,962,355 equity shares in Amerise Biosciences Ltd. This acquisition represents a 9.02% holding in the target company. The shares were acquired through open market transactions. The total equity share capital of Amerise Biosciences before and after the acquisition remains Rs. 6,60,69,000/-, comprising 66,06,900 equity shares of Rs. 10/- each. This disclosure is made under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011.

Snehjeev Ventures Pvt Ltd, along with Persons Acting in Concert (PACs), has disclosed a reduction in their shareholding in Amerise Biosciences Ltd. The acquisition/sale, conducted via open market, resulted in their stake decreasing from 9.31% to 8.83%. The transaction involved the sale of 318,285 shares, bringing the total holding of Snehjeev Ventures and its PACs to 5,835,161 shares. The total equity share capital of Amerise Biosciences is Rs. 6,60,69,000/-.

Snehjeev Ventures Pvt Ltd and its Persons Acting in Concert (PACs) have disclosed the sale of 318,285 equity shares in Amerise Biosciences Ltd. This transaction, executed via the open market on July 15, 2026, resulted in their total shareholding falling below the 9% threshold. Prior to the sale, Snehjeev Ventures and PACs held 6,153,446 shares, representing 9.31% of the total capital. After the sale, their holding reduced to 5,835,161 shares, constituting 8.83% of the company's equity. The disclosure was made under SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011.